Experimental treatment offered to patients with rare metabolic disorder
NCT ID NCT03773770
Summary
This program provides access to an experimental medication called triheptanoin for patients with Long Chain Fatty Acid Oxidation Disorders (LC-FAOD). It's for patients who have limited treatment options and cannot participate in clinical trials. The goal is to help manage this rare metabolic condition by providing an alternative energy source for the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG CHAIN FATTY ACID OXIDATION DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.